Network Pharmacology and Bioinformatics Methods Reveal the Mechanism of Sishenwan in the Treatment of diabetic nephropathy

Yuanyuan Deng,Yu Ma,Sai Zhang,Mianzhi Zhang
DOI: https://doi.org/10.1101/2023.02.14.528457
2023-01-01
Abstract:Objective . In order to decipher the bioactive components and potential mechanisms of the traditional Chinese medicine (TCM) formula Sishenwan (SSW) for diabetic nephropathy (DN), we integrated network pharmacology and bioinformatics. Methods . The candidate compounds of SSW and relative targets were obtained from the TCMSP, BATMAN-TCM, SiwssTartgetPrediction, STITCH, and ChEMBL web servers. The UniProt database was used to translate the target names into gene names, and then constructed the herbal-compound-target network. DN-related targets were ascertained based on OMIM, CTD, GeneCards, DisGeNET, and GEO. Furthermore, there was a protein-protein interaction (PPI) network to explore the overlapping targets between SSW and DN, which focused on screening the pivotal targets by topology. GO and KEGG enrichment analyses were carried out to further understand the potential functions associated with the effect of SSW against DN. Eventually, molecular docking simulations were performed to validate the binding affinity between major bioactive components and hub genes. Results. A total of 120 candidate active compounds and 542 corresponding drug targets were derived, in which 195 targets intersected with DN. Then, KEGG pathway analysis showed that several signaling pathways were closely related to the process of SSW against DN, including the AGE-RAGE signaling pathway in diabetic complications, the TNF signaling pathway, and IL-17 signaling pathway, ect. The PPI network analysis identified PTGS2, CREB1, ESR1, TNF, IL1B, INS, AKT1, PPARG , and JUN were the top 9 hub targets. The molecular docking confirmed that the bioactive compounds of SSW had a firm binding affinity with hub targets. Conclusions . As a whole, the present study revealed that SSW exerted therapeutic effects on DN via modulating multi-targets with multi-compounds through multi-pathways. ### Competing Interest Statement The authors declared that there are on conflicts of interest regarding the publication of this paper. * SSW : Sishenwan DN : Diabetic Nephropathy TCMSP : Traditional Chinese Medicine Systems Pharmacology DL : Drug-likeness OB : Oral bioavailability GO : Gene ontology BP : Biological process ALB : Albumin KEGG : Kyoto Encyclopedia of Genes and Genomes PTGS2 : Prostaglandin-endoperoxide synthase 2 CREB1 : cAMP-response element binding protein ESR1 : Estrogen receptor 1 TNF : tumor necrosis factor IL1B : Interleukin-1β INS : insulin AKT1 : AKT serine/threonine kinase 1 PPARG : Peroxisome proliferator-activated receptor gamma CC : Cellular component MF : Molecular Function TCM : Traditional Chinese medicine
What problem does this paper attempt to address?